Home » Newsletters » BioWorld Science

BioWorld Science

June 21, 2010

View Archived Issues

Japanese researchers discover novel ACAT-2 inhibitors

AFQ-056 reduces levodopa-induced dyskinesia in Parkinson's disease

Chugai Pharmaceutical claims novel prodrugs for cancer therapy

Merz describes new mGlu5 receptor modulators

Bayer Schering discloses new vasopressin receptor modulators

Scientists identify potent and selective IDE inhibitors with a new mode of action

IRX acquires funds to advance anticancer agent citoplurikin

FDA approves SanBio's phase I/IIa trial of SB-623 for stroke recovery

Trius and FDA agree on phase III trial protocol for torezolid phosphate

Interim phase II data presented on vorinostat/gemtuzumab ozogamicin in AML

MIP-3-alpha level in serum functions as prognostic biomarker in colorectal cancer

Merck & Co. presents promising clinical data on MK-4827, MK-1775 and MK-0752

ADL-5859 and ADL-5747 do not meet primary endpoint in phase IIa trial in OA pain

Covidien and Somanetics announce merger agreement

Neurocrine and Boehringer to develop GPR119 agonists for type 2 diabetes

GlaxoSmithKline identifies new orexin receptor antagonists

CanBas and Takeda to terminate collaboration for anticancer agent CBP-501

FDA schedules review of Alkermes' Vivitrol sNDA for opioid dependence

FDA issues PDUFA action date for Orexigen's Contrave obesity therapy

EC grants orphan status to pralatrexate for cutaneous T-cell lymphoma

Arno Therapeutics doses first patient in phase I/IIa trial of AR-42

Mymetics' malaria vaccine produces antibody responses in phase Ib trial

Inotek begins phase II trial of INO-8875 eye drops in glaucoma

FDA approves Novartis' Tasigna for newly diagnosed Ph+ CML

Epogin injection syringe 24000 approved for blood transfusion in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.